These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30556932)

  • 1. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma.
    Verma G; Chawla S; Mohan S; Wang S; Nasrallah M; Sheriff S; Desai A; Brem S; O'Rourke DM; Wolf RL; Maudsley AA; Poptani H
    NMR Biomed; 2019 Feb; 32(2):e4042. PubMed ID: 30556932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis.
    Sidibe I; Tensaouti F; Gilhodes J; Cabarrou B; Filleron T; Desmoulin F; Ken S; Noël G; Truc G; Sunyach MP; Charissoux M; Magné N; Lotterie JA; Roques M; Péran P; Cohen-Jonathan Moyal E; Laprie A
    Radiother Oncol; 2023 Apr; 181():109486. PubMed ID: 36706959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.
    de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S
    J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A deep learning model for discriminating true progression from pseudoprogression in glioblastoma patients.
    Moassefi M; Faghani S; Conte GM; Kowalchuk RO; Vahdati S; Crompton DJ; Perez-Vega C; Cabreja RAD; Vora SA; Quiñones-Hinojosa A; Parney IF; Trifiletti DM; Erickson BJ
    J Neurooncol; 2022 Sep; 159(2):447-455. PubMed ID: 35852738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.
    Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S
    NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors.
    Server A; Josefsen R; Kulle B; Maehlen J; Schellhorn T; Gadmar Ø; Kumar T; Haakonsen M; Langberg CW; Nakstad PH
    Acta Radiol; 2010 Apr; 51(3):316-25. PubMed ID: 20092374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
    Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
    Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury.
    Elias AE; Carlos RC; Smith EA; Frechtling D; George B; Maly P; Sundgren PC
    Acad Radiol; 2011 Sep; 18(9):1101-8. PubMed ID: 21820634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.
    Ratai EM; Zhang Z; Fink J; Muzi M; Hanna L; Greco E; Richards T; Kim D; Andronesi OC; Mintz A; Kostakoglu L; Prah M; Ellingson B; Schmainda K; Sorensen G; Barboriak D; Mankoff D; Gerstner ER;
    PLoS One; 2018; 13(6):e0198548. PubMed ID: 29902200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma.
    El-Abtah ME; Talati P; Fu M; Chun B; Clark P; Peters A; Ranasinghe A; He J; Rapalino O; Batchelor TT; Gilberto Gonzalez R; Curry WT; Dietrich J; Gerstner ER; Ratai EM
    Neurooncol Adv; 2022; 4(1):vdac128. PubMed ID: 36071927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
    Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
    J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major Metabolite Levels of Preoperative Proton Magnetic Resonance Sectroscopy and Intraoperative Fluorescence Intensity in Glioblastoma.
    Tian HL; Zu YL; Wang CC; Lin T; Guo ZT; Jiang B; Yin X; Guo WQ; Wang ZG
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):511-517. PubMed ID: 28877829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma.
    Akbari H; Rathore S; Bakas S; Nasrallah MP; Shukla G; Mamourian E; Rozycki M; Bagley SJ; Rudie JD; Flanders AE; Dicker AP; Desai AS; O'Rourke DM; Brem S; Lustig R; Mohan S; Wolf RL; Bilello M; Martinez-Lage M; Davatzikos C
    Cancer; 2020 Jun; 126(11):2625-2636. PubMed ID: 32129893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DC-AL GAN: Pseudoprogression and true tumor progression of glioblastoma multiform image classification based on DCGAN and AlexNet.
    Li M; Tang H; Chan MD; Zhou X; Qian X
    Med Phys; 2020 Mar; 47(3):1139-1150. PubMed ID: 31885094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.
    Wang S; Martinez-Lage M; Sakai Y; Chawla S; Kim SG; Alonso-Basanta M; Lustig RA; Brem S; Mohan S; Wolf RL; Desai A; Poptani H
    AJNR Am J Neuroradiol; 2016 Jan; 37(1):28-36. PubMed ID: 26450533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation injury to the normal brain measured by 3D-echo-planar spectroscopic imaging and diffusion tensor imaging: initial experience.
    Chawla S; Wang S; Kim S; Sheriff S; Lee P; Rengan R; Lin A; Melhem E; Maudsley A; Poptani H
    J Neuroimaging; 2015; 25(1):97-104. PubMed ID: 24279509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of MRSI Major Metabolite Ratios in Differentiating Between Intracerebral Ring-Enhancing Neoplastic and Non-Neoplastic Lesions, High-Grade Gliomas and Metastases, and High-Grade and Low-Grade Gliomas.
    Ankush A; Sardessai S
    Cureus; 2022 Nov; 14(11):e31841. PubMed ID: 36579207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation analysis of expressions of PTEN and p53 with the value obtained by magnetic resonance spectroscopy and apparent diffusion coefficient in the tumor and the tumor-adjacent area in magnetic resonance imaging for glioblastoma.
    Li Y; Ji F; Jiang Y; Zhao T; Xu C
    J BUON; 2018; 23(2):391-397. PubMed ID: 29745082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
    Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.